Conivaptan

Generic Name: Conivaptan

Brand Names: Vaprisol

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₂₆N_₄O_₂

CAS Number: 210101-16-9

Unique Ingredient Identifier: 0NJ98Y462X

Background: Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).

Indication: For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.

Associated Conditions: Euvolemic Hyponatremia, Hypervolemic Hyponatremia

Associated Therapies: -

Clinical Trials

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Phase 1

Completed

Conditions: Cerebral Hemorrhage
Cerebral Edema
Intracerebral Hemorrhage
Stroke

Interventions: Drug: Conivaptan

First Posted Date: 2016-12-22

Last Posted Date: 2020-04-17

Lead Sponsor: Jesse Corry

Target Recruit Count: 7

Registration Number: NCT03000283

Locations: 🇺🇸
United Hospital, Saint Paul, Minnesota, United States

Study of Stroke Related Edema Treatments

Phase 2

Withdrawn

Conditions: Acute Cerebrovascular Accident
Cerebral Edema

Interventions: Drug: Hypertonic saline
Drug: Conivaptan
Drug: Mannitol

First Posted Date: 2013-10-01

Last Posted Date: 2016-12-14

Lead Sponsor: University of Florida

Registration Number: NCT01954290

Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo (Dextrose)
Drug: Conivaptan

First Posted Date: 2012-12-19

Last Posted Date: 2015-06-17

Lead Sponsor: Finn Gustafsson

Target Recruit Count: 20

Registration Number: NCT01752543

Locations: 🇩🇰
Department of Cardiology, Copenhagen University Hospital, Rigshospital, Copenhagen, Denmark

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

Not Applicable

Conditions: Heart Failure

Interventions: Drug: Conivaptan and furosemide
Drug: Conivaptan
Drug: Furosemide

First Posted Date: 2009-06-18

Last Posted Date: 2009-06-18

Lead Sponsor: Hennepin County Medical Center, Minneapolis

Target Recruit Count: 8

Registration Number: NCT00924014

Locations: 🇺🇸
Hennepin county Medical Center, Minneapolis, Minnesota, United States

Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

Phase 3

Terminated

Conditions: Hyponatremia
Acute Decompensated Heart Failure

Interventions: Drug: placebo
Drug: conivaptan

First Posted Date: 2009-02-13

Last Posted Date: 2014-05-15

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT00843986

Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion

Phase 4

Withdrawn

Conditions: Heart Failure

Interventions: Other: Placebo
Drug: Conivaptan

First Posted Date: 2008-12-11

Last Posted Date: 2011-06-23

Lead Sponsor: Albert Einstein Healthcare Network

Registration Number: NCT00806910

Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

Phase 4

Terminated

Conditions: Hyponatremia

Interventions: Drug: Conivaptan

First Posted Date: 2008-08-01

Last Posted Date: 2022-03-28

Lead Sponsor: Northwestern University

Target Recruit Count: 6

Registration Number: NCT00727090

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

Phase 3

Withdrawn

Conditions: Hyponatremia

Interventions: Other: D5
Drug: Conivaptan

First Posted Date: 2008-05-26

Last Posted Date: 2015-03-06

Lead Sponsor: Columbia University

Registration Number: NCT00684164

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

Phase 2

Completed

Conditions: Liver Cirrhosis

Interventions: Drug: conivaptan
Drug: Placebo

First Posted Date: 2008-01-14

Last Posted Date: 2014-05-15

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT00592475

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Phase 3

Completed

Conditions: Hyponatremia

Interventions: Drug: Conivaptan
Drug: Placebo

First Posted Date: 2007-05-24

Last Posted Date: 2014-05-15

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT00478192

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy